These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 29064732)

  • 21. Generation and characterization of chimeric recombinant AAV vectors.
    Hauck B; Chen L; Xiao W
    Mol Ther; 2003 Mar; 7(3):419-25. PubMed ID: 12668138
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic efficacy of bone marrow transplant, intracranial AAV-mediated gene therapy, or both in the mouse model of MPS IIIB.
    Heldermon CD; Ohlemiller KK; Herzog ED; Vogler C; Qin E; Wozniak DF; Tan Y; Orrock JL; Sands MS
    Mol Ther; 2010 May; 18(5):873-80. PubMed ID: 20179679
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficiency of eight different AAV serotypes in transducing rat myocardium in vivo.
    Palomeque J; Chemaly ER; Colosi P; Wellman JA; Zhou S; Del Monte F; Hajjar RJ
    Gene Ther; 2007 Jul; 14(13):989-97. PubMed ID: 17251988
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence and long-term monitoring of humoral immunity against adeno-associated virus in Duchenne Muscular Dystrophy patients.
    Leborgne C; Latournerie V; Boutin S; Desgue D; Quéré A; Pignot E; Collaud F; Charles S; Simon Sola M; Masat E; Jouen F; Boyer O; Masurier C; Mingozzi F; Veron P
    Cell Immunol; 2019 Aug; 342():103780. PubMed ID: 29571923
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia.
    Li C; Narkbunnam N; Samulski RJ; Asokan A; Hu G; Jacobson LJ; Manco-Johnson MJ; Monahan PE;
    Gene Ther; 2012 Mar; 19(3):288-94. PubMed ID: 21697954
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neutralizing Antibodies Against Adeno-Associated Viral Capsids in Patients with mut Methylmalonic Acidemia.
    Harrington EA; Sloan JL; Manoli I; Chandler RJ; Schneider M; McGuire PJ; Calcedo R; Wilson JM; Venditti CP
    Hum Gene Ther; 2016 May; 27(5):345-53. PubMed ID: 26790480
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Preclinical Study in Rhesus Macaques for Cystic Fibrosis to Assess Gene Transfer and Transduction by AAV1 and AAV5 with a Dual-Luciferase Reporter System.
    Guggino WB; Benson J; Seagrave J; Yan Z; Engelhardt J; Gao G; Conlon TJ; Cebotaru L
    Hum Gene Ther Clin Dev; 2017 Sep; 28(3):145-156. PubMed ID: 28726496
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Threshold for Pre-existing Antibody Levels Limiting Transduction Efficiency of Systemic rAAV9 Gene Delivery: Relevance for Translation.
    Meadows AS; Pineda RJ; Goodchild L; Bobo TA; Fu H
    Mol Ther Methods Clin Dev; 2019 Jun; 13():453-462. PubMed ID: 31193101
    [TBL] [Abstract][Full Text] [Related]  

  • 29. AAV Natural Infection Induces Broad Cross-Neutralizing Antibody Responses to Multiple AAV Serotypes in Chimpanzees.
    Calcedo R; Wilson JM
    Hum Gene Ther Clin Dev; 2016 Jun; 27(2):79-82. PubMed ID: 27314914
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low Seroprevalence of Neutralizing Antibodies Targeting Two Clade F AAV in Humans.
    Ellsworth JL; O'Callaghan M; Rubin H; Seymour A
    Hum Gene Ther Clin Dev; 2018 Mar; 29(1):60-67. PubMed ID: 29624457
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence of AAV1 neutralizing antibodies and consequences for a clinical trial of gene transfer for advanced heart failure.
    Greenberg B; Butler J; Felker GM; Ponikowski P; Voors AA; Pogoda JM; Provost R; Guerrero J; Hajjar RJ; Zsebo KM
    Gene Ther; 2016 Mar; 23(3):313-9. PubMed ID: 26699914
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction of robust immune responses against human immunodeficiency virus is supported by the inherent tropism of adeno-associated virus type 5 for dendritic cells.
    Xin KQ; Mizukami H; Urabe M; Toda Y; Shinoda K; Yoshida A; Oomura K; Kojima Y; Ichino M; Klinman D; Ozawa K; Okuda K
    J Virol; 2006 Dec; 80(24):11899-910. PubMed ID: 17005662
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Feasibility and safety of systemic rAAV9-hNAGLU delivery for treating mucopolysaccharidosis IIIB: toxicology, biodistribution, and immunological assessments in primates.
    Murrey DA; Naughton BJ; Duncan FJ; Meadows AS; Ware TA; Campbell KJ; Bremer WG; Walker CM; Goodchild L; Bolon B; La Perle K; Flanigan KM; McBride KL; McCarty DM; Fu H
    Hum Gene Ther Clin Dev; 2014 Jun; 25(2):72-84. PubMed ID: 24720466
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disease correction by combined neonatal intracranial AAV and systemic lentiviral gene therapy in Sanfilippo Syndrome type B mice.
    Heldermon CD; Qin EY; Ohlemiller KK; Herzog ED; Brown JR; Vogler C; Hou W; Orrock JL; Crawford BE; Sands MS
    Gene Ther; 2013 Sep; 20(9):913-21. PubMed ID: 23535899
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adeno-associated virus (AAV) vectors in gene therapy: immune challenges and strategies to circumvent them.
    Hareendran S; Balakrishnan B; Sen D; Kumar S; Srivastava A; Jayandharan GR
    Rev Med Virol; 2013 Nov; 23(6):399-413. PubMed ID: 24023004
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative analysis of adeno-associated virus serotypes for gene transfer in organotypic heart slices.
    Liu Z; Klose K; Neuber S; Jiang M; Gossen M; Stamm C
    J Transl Med; 2020 Nov; 18(1):437. PubMed ID: 33208161
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cell-Mediated Immunity to NAGLU Transgene Following Intracerebral Gene Therapy in Children With Mucopolysaccharidosis Type IIIB Syndrome.
    Gougeon ML; Poirier-Beaudouin B; Ausseil J; Zérah M; Artaud C; Heard JM; Deiva K; Tardieu M
    Front Immunol; 2021; 12():655478. PubMed ID: 34040605
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy.
    Louis Jeune V; Joergensen JA; Hajjar RJ; Weber T
    Hum Gene Ther Methods; 2013 Apr; 24(2):59-67. PubMed ID: 23442094
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adeno-associated virus vector serotypes mediate sustained correction of bilirubin UDP glucuronosyltransferase deficiency in rats.
    Seppen J; Bakker C; de Jong B; Kunne C; van den Oever K; Vandenberghe K; de Waart R; Twisk J; Bosma P
    Mol Ther; 2006 Jun; 13(6):1085-92. PubMed ID: 16581301
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of neutralizing antibodies against liver-tropic adeno-associated virus serotype vectors in 100 healthy Chinese and its potential relation to body constitutions.
    Ling C; Wang Y; Feng YL; Zhang YN; Li J; Hu XR; Wang LN; Zhong MF; Zhai XF; Zolotukhin I; Srivastava A; Ling CQ
    J Integr Med; 2015 Sep; 13(5):341-6. PubMed ID: 26343106
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.